Dominic Piscitelli
2021 - Oric Pharmaceuticals
In 2021, Dominic Piscitelli earned a total compensation of $2.6M as Chief Financial Officer at Oric Pharmaceuticals, a 63% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $199,300 |
|---|---|
| Option Awards | $1,958,220 |
| Salary | $398,518 |
| Other | $12,206 |
| Total | $2,568,244 |
Piscitelli received $2M in option awards, accounting for 76% of the total pay in 2021.
Piscitelli also received $199.3K in non-equity incentive plan, $398.5K in salary and $12.2K in other compensation.
Rankings
In 2021, Dominic Piscitelli's compensation ranked 5,051st out of 12,406 executives tracked by ExecPay. In other words, Piscitelli earned more than 59.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,051 out of 12,406 | 59th |
Division Manufacturing | 2,124 out of 5,492 | 61st |
Major group Chemicals And Allied Products | 908 out of 2,368 | 62nd |
Industry group Drugs | 812 out of 2,089 | 61st |
Industry Pharmaceutical Preparations | 580 out of 1,536 | 62nd |
Source: SEC filing on April 27, 2022.
Piscitelli's colleagues
We found two more compensation records of executives who worked with Dominic Piscitelli at Oric Pharmaceuticals in 2021.
News
Oric Pharmaceuticals CEO Jacob Chacko's 2023 pay falls 28% to $3.2M
April 24, 2024
Oric Pharmaceuticals CEO Jacob Chacko's 2022 pay falls 37% to $4.4M
April 26, 2023
Oric Pharmaceuticals CEO Jacob Chacko's 2021 pay rises 19% to $7M
April 27, 2022
Oric Pharmaceuticals CEO Jacob Chacko's 2020 pay jumps 774% to $5.9M
April 26, 2021
ANAPTYSBIO CEO Hamza Suria's 2019 pay jumps 54% to $7.9M
April 27, 2020
ANAPTYSBIO CEO Hamza Suria's 2018 pay jumps 28% to $5.1M
April 26, 2019